Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push - Reuters
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOX0g4M0x4Zk1xRGRkS2ktTmo0SEJKZ3dSc2NWQzk2Zm83TkVTODZHaGVsdmtocHBJMEdaQTZKX3pTVnA1a0pweHBlZDZPVWJTWDMyM0l0OTROcnJFdGhCMURwUUtvQlh3OVBwRHQyZjd6cmJxVk1qdE9NUkVMeDY4S2JZQWtFMVc3NGlNbFM3T0s3dHZBVmxWeXdzN05OSUFvZ2xCYQ?oc=5" target="_blank">Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026 at 04:14 PMBayer to invest $2.2 billion in new US pharma site - Reuters
Bayer to invest $2.2 billion in new US pharma site Reuters
October 2, 2026 at 07:19 PMSanofi to pay Regeneron $1 billion upfront in expanded immunology deal - Reuters
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal Reuters
October 1, 2026 at 05:17 AMAstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up Reuters
September 28, 2026 at 10:15 PMNovartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026 at 10:57 AMLilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com
Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com
September 29, 2026 at 10:15 PM